https://www.trianglehealth.com/ weekly 1 https://www.trianglehealth.com/es weekly 1 https://www.trianglehealth.com/about-us monthly 0.8 https://www.trianglehealth.com/es/about-us monthly 0.8 https://www.trianglehealth.com/for-patients monthly 0.8 https://www.trianglehealth.com/es/for-patients monthly 0.8 https://www.trianglehealth.com/evidence monthly 0.8 https://www.trianglehealth.com/es/evidence monthly 0.8 https://www.trianglehealth.com/pricing monthly 0.8 https://www.trianglehealth.com/es/pricing monthly 0.8 https://www.trianglehealth.com/faq monthly 0.8 https://www.trianglehealth.com/es/faq monthly 0.8 https://www.trianglehealth.com/phase-1 2026-10-30T00:00:00.000Z monthly 0.8 https://www.trianglehealth.com/es/phase-1 2026-10-30T00:00:00.000Z monthly 0.8 https://www.trianglehealth.com/phase-1/idh1-peptide-vaccine 2018-11-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/idh1-peptide-vaccine 2018-11-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ras-on-g12d 2026-06-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ras-on-g12d 2026-06-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/claudin6-car-t 2026-06-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/claudin6-car-t 2026-06-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pnoc020-nct04573140 2026-10-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pnoc020-nct04573140 2026-10-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/revlimid-lenalidomide-nct03223610 2026-10-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/revlimid-lenalidomide-nct03223610 2026-10-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/eli-002-7p-nct07671339 2026-10-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/eli-002-7p-nct07671339 2026-10-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ultrasound-induced-microbubble-cavitation-nct07501650 2026-10-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ultrasound-induced-microbubble-cavitation-nct07501650 2026-10-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd19-cd22-car-transduced-t-cells-nct05442515 2026-10-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd19-cd22-car-transduced-t-cells-nct05442515 2026-10-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/adept-nct07346144 2026-10-23T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/adept-nct07346144 2026-10-23T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/chimeric-antigen-receptor-t-cell-therapy-nct06815029 2026-10-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/chimeric-antigen-receptor-t-cell-therapy-nct06815029 2026-10-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lm-gucy2c-vaccine-nct07417488 2026-10-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lm-gucy2c-vaccine-nct07417488 2026-10-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pmd-026-nct07379125 2026-10-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pmd-026-nct07379125 2026-10-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/car-t-cell-nct05003895 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/car-t-cell-nct05003895 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd22cart-cell-nct04815356 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd22cart-cell-nct04815356 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/fgfr4-car-t-cells-nct06865664 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/fgfr4-car-t-cells-nct06865664 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lu-177-dotatate-nct04086485 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lu-177-dotatate-nct04086485 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tnhyp218-car-t-cells-nct06885697 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tnhyp218-car-t-cells-nct06885697 2026-10-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/danvatirsen-nct05986240 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/danvatirsen-nct05986240 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/photodynamic-therapy-nct06307548 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/photodynamic-therapy-nct06307548 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/il13ralpha2-specific-hinge-optimized-41bb-co-stimulatory-nct04510051 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/il13ralpha2-specific-hinge-optimized-41bb-co-stimulatory-nct04510051 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/m28z1xxpd1dnr-car-nct06623396 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/m28z1xxpd1dnr-car-nct06623396 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/nt-i7-nct07200089 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/nt-i7-nct07200089 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pomalidomide-nct07532525 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pomalidomide-nct07532525 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/selinexor-nct07200102 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/selinexor-nct07200102 2026-10-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/impact-nct06193759 2026-10-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/impact-nct06193759 2026-10-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd79b-19-car-t-cells-nct06026319 2026-10-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd79b-19-car-t-cells-nct06026319 2026-10-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lnk001-nct07564232 2026-10-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lnk001-nct07564232 2026-10-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/venetoclax-nct06129734 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/venetoclax-nct06129734 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/honokiol-nct06566443 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/honokiol-nct06566443 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07509008 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07509008 2026-10-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd371-specific-ysnvz-i-18-car-t-cells-nct06017258 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd371-specific-ysnvz-i-18-car-t-cells-nct06017258 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/rabbit-nct06814496 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/rabbit-nct06814496 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ziftomenib-nct06440135 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ziftomenib-nct06440135 2026-10-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/neo-combatxl-nct06902376 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/neo-combatxl-nct06902376 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/allogeneic-anti-ny-eso-1-tcr-il-15-transduced-cord-blood-nct06066359 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/allogeneic-anti-ny-eso-1-tcr-il-15-transduced-cord-blood-nct06066359 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/nk-cells-nct07411599 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/nk-cells-nct07411599 2026-10-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/rely-30-nct02917083 2026-10-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/rely-30-nct02917083 2026-10-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/durvalumab-tremelimumab-nct05932199 2026-10-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/durvalumab-tremelimumab-nct05932199 2026-10-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/15-gpc3-car-t-cells-nct06815432 2026-09-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/15-gpc3-car-t-cells-nct06815432 2026-09-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/nt-i7-nct07052305 2026-09-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/nt-i7-nct07052305 2026-09-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lomustine-nct07145112 2026-09-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lomustine-nct07145112 2026-09-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/abemaciclib-nct04923542 2026-09-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/abemaciclib-nct04923542 2026-09-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/navlimetostat-nct07579221 2026-09-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/navlimetostat-nct07579221 2026-09-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/oncolytic-adenovirus-ad5-dnx-2401-nct03896568 2026-09-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/oncolytic-adenovirus-ad5-dnx-2401-nct03896568 2026-09-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/epcoritamab-nct06672705 2026-09-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/epcoritamab-nct06672705 2026-09-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ruxolitinib-nct03874052 2026-09-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ruxolitinib-nct03874052 2026-09-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/crd3874-si-nct07661095 2026-09-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/crd3874-si-nct07661095 2026-09-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/neratinib-pill-nct05274048 2026-09-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/neratinib-pill-nct05274048 2026-09-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/zanu-tafa-nct06029309 2026-09-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/zanu-tafa-nct06029309 2026-09-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/egfr-inhibitor-eras-801-nct07089641 2026-09-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/egfr-inhibitor-eras-801-nct07089641 2026-09-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/venetoclax-nct03214562 2026-09-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/venetoclax-nct03214562 2026-09-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cladribine-nct04375631 2026-09-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cladribine-nct04375631 2026-09-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tepotinib-nct07619339 2026-09-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tepotinib-nct07619339 2026-09-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tumor-infiltrating-lymphocytes-til-nct05681780 2026-09-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tumor-infiltrating-lymphocytes-til-nct05681780 2026-09-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lifileucel-ln-144-ln-145-nct05607095 2026-09-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lifileucel-ln-144-ln-145-nct05607095 2026-09-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/2141-v11-nct07818018 2026-09-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/2141-v11-nct07818018 2026-09-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/recombinant-interferon-alpha-2b-like-protein-nct04380545 2026-09-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/recombinant-interferon-alpha-2b-like-protein-nct04380545 2026-09-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/dt2216-nct06964009 2026-09-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/dt2216-nct06964009 2026-09-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sx-682-nct07814352 2026-09-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sx-682-nct07814352 2026-09-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/neural-stem-cells-expressing-crad-s-pk7-nct05139056 2026-09-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/neural-stem-cells-expressing-crad-s-pk7-nct05139056 2026-09-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tafasitamab-nct07225439 2026-09-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tafasitamab-nct07225439 2026-09-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07444632 2026-09-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tgfbr2-ko-car27-il-15-nk-cells-nct07444632 2026-09-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cord-blood-derived-expanded-allogeneic-natural-killer-ce-nct04991870 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cord-blood-derived-expanded-allogeneic-natural-killer-ce-nct04991870 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/g207-nct03911388 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/g207-nct03911388 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/mesenchymal-stromal-cells-derived-exosomes-with-kras-g12-nct03608631 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/mesenchymal-stromal-cells-derived-exosomes-with-kras-g12-nct03608631 2026-09-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/b7-h3-cd28z-cart-nct07390539 2026-09-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/b7-h3-cd28z-cart-nct07390539 2026-09-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/mir-126-inhibitor-miristen-nct07025564 2026-09-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/mir-126-inhibitor-miristen-nct07025564 2026-09-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/high-dose-ascorbate-nct07177079 2026-08-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/high-dose-ascorbate-nct07177079 2026-08-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/inm176-nct06600698 2026-08-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/inm176-nct06600698 2026-08-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06152809 2026-08-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06152809 2026-08-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/axatilimab-nct06523556 2026-08-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/axatilimab-nct06523556 2026-08-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/carlotta01-nct05836896 2026-08-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/carlotta01-nct05836896 2026-08-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/gavel-nct07439211 2026-08-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/gavel-nct07439211 2026-08-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/prmt5-inhibitor-bms-986504-nct07594626 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/prmt5-inhibitor-bms-986504-nct07594626 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/epcoritamab-nct06536049 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/epcoritamab-nct06536049 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/nk-cells-nct07579208 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/nk-cells-nct07579208 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pomalidomide-nct05389423 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pomalidomide-nct05389423 2026-08-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/victory-nct05609994 2026-08-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/victory-nct05609994 2026-08-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/abcd-nk-nct06158828 2026-08-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/abcd-nk-nct06158828 2026-08-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/autologous-anti-psca-car-4-1bb-tcrzeta-cd19t-expressing-nct05805371 2026-08-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/autologous-anti-psca-car-4-1bb-tcrzeta-cd19t-expressing-nct05805371 2026-08-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/fluoxetine-nct06225011 2026-08-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/fluoxetine-nct06225011 2026-08-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/brite-nct04903795 2026-08-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/brite-nct04903795 2026-08-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/chimeric-antigen-receptor-t-cells-nct05225363 2026-08-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/chimeric-antigen-receptor-t-cells-nct05225363 2026-08-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/prism-nct07139990 2026-08-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/prism-nct07139990 2026-08-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sacituzumab-nct06040970 2026-08-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sacituzumab-nct06040970 2026-08-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sabre-nct07172958 2026-08-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sabre-nct07172958 2026-08-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/brachytherapy-nct06543576 2026-08-12T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/brachytherapy-nct06543576 2026-08-12T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/magenta-nct03081910 2026-08-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/magenta-nct03081910 2026-08-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/valemetostat-nct06807632 2026-08-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/valemetostat-nct06807632 2026-08-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/bcma-tgf-car-t-cells-0-50-x-10-6-cells-kg-nct05976555 2026-08-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/bcma-tgf-car-t-cells-0-50-x-10-6-cells-kg-nct05976555 2026-08-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/solar-nct06607549 2026-08-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/solar-nct06607549 2026-08-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/car-70-il15-transduced-cb-nk-cells-nct05092451 2026-08-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/car-70-il15-transduced-cb-nk-cells-nct05092451 2026-08-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/care-t-cells-nct04715191 2026-08-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/care-t-cells-nct04715191 2026-08-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/folr1-car-t-cells-nct06609928 2026-08-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/folr1-car-t-cells-nct06609928 2026-08-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/riot-4a-nct07192900 2026-08-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/riot-4a-nct07192900 2026-08-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/c7r-gd2-cart-cells-iv-and-icv-infusion-nct04099797 2026-08-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/c7r-gd2-cart-cells-iv-and-icv-infusion-nct04099797 2026-08-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lenvatinib-nct05603910 2026-08-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lenvatinib-nct05603910 2026-08-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/durvalumab-nct03011814 2026-07-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/durvalumab-nct03011814 2026-07-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ig-imrt-nct01659203 2026-07-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ig-imrt-nct01659203 2026-07-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/archer-nct05950139 2026-07-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/archer-nct05950139 2026-07-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/fenofibrate-nct06191133 2026-07-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/fenofibrate-nct06191133 2026-07-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/astx727-nct03922555 2026-07-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/astx727-nct03922555 2026-07-24T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/dupilumab-nct06088771 2026-07-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/dupilumab-nct06088771 2026-07-21T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/lutathera-lutetium-lu-177-dotatate-nct05278208 2026-07-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/lutathera-lutetium-lu-177-dotatate-nct05278208 2026-07-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ipilimumab-nct07128680 2026-07-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ipilimumab-nct07128680 2026-07-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/177lu-rhpsma-10-1-nct06066437 2026-07-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/177lu-rhpsma-10-1-nct06066437 2026-07-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/inotuzumab-ozogamicin-nct01371630 2026-07-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/inotuzumab-ozogamicin-nct01371630 2026-07-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/carv3-team-e-t-cells-nct05660369 2026-07-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/carv3-team-e-t-cells-nct05660369 2026-07-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pemigatinib-nct04659616 2026-07-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pemigatinib-nct04659616 2026-07-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/flinn-nct07355205 2026-07-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/flinn-nct07355205 2026-07-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd19x22-car-t-cells-nct05098613 2026-07-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd19x22-car-t-cells-nct05098613 2026-07-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ws-cart-cs1-nct06185751 2026-07-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ws-cart-cs1-nct06185751 2026-07-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/mosunetuzumab-nct06249191 2026-07-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/mosunetuzumab-nct06249191 2026-07-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/emapalumab-nct06996119 2026-07-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/emapalumab-nct06996119 2026-07-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/combination-treatment-cxrpt-of-external-beam-radiation-x-nct04892303 2026-06-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/combination-treatment-cxrpt-of-external-beam-radiation-x-nct04892303 2026-06-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/papaverine-nct05136846 2026-06-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/papaverine-nct05136846 2026-06-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/gilteritinib-nct06225427 2026-06-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/gilteritinib-nct06225427 2026-06-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/starlite-nct06428045 2026-06-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/starlite-nct06428045 2026-06-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/astatine-at-211-anti-cd45-monoclonal-antibody-bc8-b10-nct03670966 2026-06-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/astatine-at-211-anti-cd45-monoclonal-antibody-bc8-b10-nct03670966 2026-06-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cyclosporine-nct03128034 2026-06-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cyclosporine-nct03128034 2026-06-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cdx-1140-nct05029999 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cdx-1140-nct05029999 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ciml-nk-nct04024761 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ciml-nk-nct04024761 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06138587 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06138587 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sitagliptin-nct07541781 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sitagliptin-nct07541781 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sl-401-nct03113643 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sl-401-nct03113643 2026-06-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06321484 2026-06-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cytokine-induced-memory-like-natural-killer-cells-nct06321484 2026-06-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ad-hcmv-flt3l-nct06914479 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ad-hcmv-flt3l-nct06914479 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/leflunomide-nct04997993 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/leflunomide-nct04997993 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/melphalan-nct04483206 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/melphalan-nct04483206 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tpt-ced-rhgg-nct06666712 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tpt-ced-rhgg-nct06666712 2026-06-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/natural-killer-cell-therapy-nct05588453 2026-06-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/natural-killer-cell-therapy-nct05588453 2026-06-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/eradicate-nct07198724 2026-06-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/eradicate-nct07198724 2026-06-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ruxolitinib-phosphate-nct07278856 2026-06-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ruxolitinib-phosphate-nct07278856 2026-06-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/177lu-psma-617-nct07223034 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/177lu-psma-617-nct07223034 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pembrolizumab-nct04297605 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct04297605 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/replay-nct07237594 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/replay-nct07237594 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sirolimus-nct07581704 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sirolimus-nct07581704 2026-06-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd19car-cd28-cd3zeta-egfrt-expressing-tn-mem-t-lymphocyt-nct05625594 2026-06-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd19car-cd28-cd3zeta-egfrt-expressing-tn-mem-t-lymphocyt-nct05625594 2026-06-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/bevacizumab-nct01269853 2026-06-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/bevacizumab-nct01269853 2026-06-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/anti-cd19-cd20-cd22-car-t-cells-nct05418088 2026-05-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/anti-cd19-cd20-cd22-car-t-cells-nct05418088 2026-05-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd123-car-t-nct04318678 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd123-car-t-nct04318678 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ont01-nct06904378 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ont01-nct06904378 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sorafenib-nct05468359 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sorafenib-nct05468359 2026-05-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/implantable-microdevice-imd-nct05700461 2026-05-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/implantable-microdevice-imd-nct05700461 2026-05-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/total-body-irradiation-nct06928662 2026-05-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/total-body-irradiation-nct06928662 2026-05-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/zanubrutinib-nct06730542 2026-05-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/zanubrutinib-nct06730542 2026-05-14T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pralatrexate-nct07225985 2026-05-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pralatrexate-nct07225985 2026-05-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/anti-garp-chimeric-antigen-receptor-t-cells-nct06964737 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/anti-garp-chimeric-antigen-receptor-t-cells-nct06964737 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/dc-mm-fusion-vaccine-nct07377435 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/dc-mm-fusion-vaccine-nct07377435 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/car-t-cell-nct06768905 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/car-t-cell-nct06768905 2026-05-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/personalized-neoantigen-dna-vaccine-nct03988283 2026-05-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/personalized-neoantigen-dna-vaccine-nct03988283 2026-05-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/dc-aml-fusion-vaccine-nct07374029 2026-05-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/dc-aml-fusion-vaccine-nct07374029 2026-05-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/gc511b-car-t-cell-nct07249879 2026-05-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/gc511b-car-t-cell-nct07249879 2026-05-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/rhdnase-i-nct07361224 2026-05-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/rhdnase-i-nct07361224 2026-05-01T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ipilimumab-and-nivolumab-nct07075120 2026-04-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ipilimumab-and-nivolumab-nct07075120 2026-04-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/enfortumab-vedotin-nct04878029 2026-04-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/enfortumab-vedotin-nct04878029 2026-04-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/seneca-valley-virus-001-svv-001-nct06889493 2026-04-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/seneca-valley-virus-001-svv-001-nct06889493 2026-04-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ivonescimab-nct07535463 2026-04-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ivonescimab-nct07535463 2026-04-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cladribine-nct04797767 2026-04-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cladribine-nct04797767 2026-04-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/intradermal-injection-of-cadi-05-nct07455032 2026-04-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/intradermal-injection-of-cadi-05-nct07455032 2026-04-15T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/magenta-nct07032714 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/magenta-nct07032714 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/mirda-nct06159166 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/mirda-nct06159166 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/scri-carb7h3-s-b7h3-specific-chimeric-antigen-receptor-c-nct04185038 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/scri-carb7h3-s-b7h3-specific-chimeric-antigen-receptor-c-nct04185038 2026-04-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cart-nct07319676 2026-04-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cart-nct07319676 2026-04-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cscc-nct05377905 2026-04-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cscc-nct05377905 2026-04-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/durable-nct05987644 2026-04-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/durable-nct05987644 2026-04-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/fostamatinib-nct06639724 2026-04-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/fostamatinib-nct06639724 2026-04-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/riot-4b-nct07443020 2026-04-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/riot-4b-nct07443020 2026-04-07T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/atra-nct06536413 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/atra-nct06536413 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/anti-cd30-bispecific-antibody-armed-anti-cd3-activated-a-nct05544968 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/anti-cd30-bispecific-antibody-armed-anti-cd3-activated-a-nct05544968 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/emavusertib-nct07107750 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/emavusertib-nct07107750 2026-04-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/flt3-mertk-inhibitor-mrx-2843-nct04762199 2026-03-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/flt3-mertk-inhibitor-mrx-2843-nct04762199 2026-03-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/adv-hsv-tk-gene-therapy-nct03596086 2026-03-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/adv-hsv-tk-gene-therapy-nct03596086 2026-03-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/eagd-t-cell-nct03533816 2026-03-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/eagd-t-cell-nct03533816 2026-03-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/revumenib-nct06313437 2026-03-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/revumenib-nct06313437 2026-03-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/withaferin-a-nct05610735 2026-03-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/withaferin-a-nct05610735 2026-03-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/folfox-nct04808323 2026-03-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/folfox-nct04808323 2026-03-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tazemetostat-nct05627232 2026-03-12T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tazemetostat-nct05627232 2026-03-12T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/db107-rrv-nct06504381 2026-03-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/db107-rrv-nct06504381 2026-03-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/acalabrutinib-nct05256641 2026-03-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/acalabrutinib-nct05256641 2026-03-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/adclec-syn1-car-t-cells-nct05748197 2026-03-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/adclec-syn1-car-t-cells-nct05748197 2026-03-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cue-102-nct06917885 2026-03-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cue-102-nct06917885 2026-03-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pembrolizumab-nct06868433 2026-03-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct06868433 2026-03-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/fhd-286-nct07283094 2026-03-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/fhd-286-nct07283094 2026-03-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/grale-nct01555892 2026-03-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/grale-nct01555892 2026-03-02T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/18f-v-6-bp-nct05452005 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/18f-v-6-bp-nct05452005 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/rituximab-nct06209619 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/rituximab-nct06209619 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/gemtuzumab-ozogamicin-nct05558124 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/gemtuzumab-ozogamicin-nct05558124 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tegavivint-nct05755087 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tegavivint-nct05755087 2026-02-27T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ciml-nk-cells-nct05580601 2026-02-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ciml-nk-cells-nct05580601 2026-02-25T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/8-12-day-production-of-car-t-cells-nct04186520 2026-02-23T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/8-12-day-production-of-car-t-cells-nct04186520 2026-02-23T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sbrt-atezolizumab-and-bevacizumab-nct05488522 2026-02-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sbrt-atezolizumab-and-bevacizumab-nct05488522 2026-02-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/atezolizumab-nct05096715 2026-02-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/atezolizumab-nct05096715 2026-02-18T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/impact-nct07148050 2026-02-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/impact-nct07148050 2026-02-17T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/nilotinib-nct04903119 2026-02-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/nilotinib-nct04903119 2026-02-13T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/roginolisib-nct06644183 2026-02-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/roginolisib-nct06644183 2026-02-11T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/adenosine-a2b-receptor-antagonist-pbf-1129-nct05234307 2026-02-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/adenosine-a2b-receptor-antagonist-pbf-1129-nct05234307 2026-02-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/vista-nct03740256 2026-02-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/vista-nct03740256 2026-02-06T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/decipher-nct05504707 2026-02-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/decipher-nct05504707 2026-02-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/tinks-nct05634369 2026-01-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/tinks-nct05634369 2026-01-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/gd2-car-t-cells-nct04196413 2026-01-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/gd2-car-t-cells-nct04196413 2026-01-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/vaccine-therapy-nct06324240 2026-01-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/vaccine-therapy-nct06324240 2026-01-26T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/m032-nct05084430 2026-01-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/m032-nct05084430 2026-01-22T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/indoximod-nct05106296 2026-01-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/indoximod-nct05106296 2026-01-09T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/talquetamab-nct07093554 2026-01-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/talquetamab-nct07093554 2026-01-05T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/sotorasib-nct05815173 2025-12-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/sotorasib-nct05815173 2025-12-30T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ad5-ycd-muttksr39rep-adp-adenovirus-nct05686798 2025-12-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ad5-ycd-muttksr39rep-adp-adenovirus-nct05686798 2025-12-16T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/spatially-fractionated-rt-nct06546969 2025-12-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/spatially-fractionated-rt-nct06546969 2025-12-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/siaci-of-cetuximab-and-bevacizumab-nct05956821 2025-12-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/siaci-of-cetuximab-and-bevacizumab-nct05956821 2025-12-08T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/pembrolizumab-nct03760575 2025-12-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/pembrolizumab-nct03760575 2025-12-04T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/dnajb1-prkaca-peptide-vaccine-nct04248569 2025-12-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/dnajb1-prkaca-peptide-vaccine-nct04248569 2025-12-03T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd19x22-car-t-nct06559189 2025-11-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd19x22-car-t-nct06559189 2025-11-28T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/phoebe-nct05900895 2025-11-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/phoebe-nct05900895 2025-11-20T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ramucirumab-nct06675136 2025-11-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ramucirumab-nct06675136 2025-11-10T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/avasopasem-nct07137871 2025-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/avasopasem-nct07137871 2025-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/adaptive-stereotactic-body-radiation-nct05880667 2025-10-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/adaptive-stereotactic-body-radiation-nct05880667 2025-10-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/ginakit2-nct03294954 2025-09-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/ginakit2-nct03294954 2025-09-19T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-1/cd19-car-t-cells-nct03676504 2024-07-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/es/phase-1/cd19-car-t-cells-nct03676504 2024-07-29T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2 2026-10-31T00:00:00.000Z weekly 0.8 https://www.trianglehealth.com/phase-2/24bro681-alternating-gnp-and-mfolfirinox-for-br-pdac-nct07043270 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/3-5-fraction-stereotactic-body-radiation-therapy-for-palliation-nct05674396 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/5-azacytidine-and-or-nivolumab-in-resectable-hpv-associated-hnsc-nct05317000 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/5-day-preoperative-radiation-for-soft-tissue-sarcoma-nct06087861 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-nct06887218 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-cancer-vaccine-stemvac-in-combination-with-chemotherapy-for-th-nct07078604 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-clinical-study-of-calderasib-mk-1084-in-people-with-advanced-s-nct07209111 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-clinical-study-of-intismeran-autogene-v940-and-pembrolizumab-m-nct06961006 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-clinical-study-of-zilovertamab-vedotin-mk-2140-plus-rituximab-nct06890884 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-long-term-treatment-extension-study-of-niraparib-in-participan-nct04641247 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-multicenter-trial-to-identify-optimal-atezolizumab-biomarkers-nct06069726 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-multiple-antigen-vaccine-stemvac-for-the-treatment-of-patients-nct05242965 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-neoadjuvant-study-of-tislelizumab-and-sx-682-for-resectable-pa-nct05604560 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-and-pharmacodynamic-study-of-sitagliptin-in-patients-w-nct07003542 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-neoadjuvant-study-of-zanidatamab-in-combination-with-c-nct07102381 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-open-label-single-arm-study-of-autologous-m-cenk-adopt-nct06710288 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-platform-study-of-immunomodulatory-compounds-in-ici-re-nct07133425 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-single-arm-open-label-pilot-trial-evaluating-zanidatam-nct05035836 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-evaluating-olutasidenib-in-patients-with-idh1-mu-nct06566742 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-acr-368-in-endometrial-adenocarcinoma-nct05548296 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-ptx-100-in-patients-with-relapsed-refractory-nct06854653 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-the-ketogenic-diet-vs-standard-anti-cancer-di-nct05708352 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-co-nct07659795 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pa-nct07644559 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-wu-cart-007-an-anti-cd7-allogeneic-car-t-cell-nct06514794 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-of-zanidatamab-in-patients-with-her2-expressing-nct06695845 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-to-evaluate-efficacy-of-calaspargase-pegol-mknl-nct06561074 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-study-to-evaluate-the-effects-of-asp5541-in-participan-nct07005154 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-for-metastatic-melanoma-using-adoptive-cell-ther-nct02621021 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-ivonescimab-for-patients-with-advanced-metast-nct06805617 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-mosunetuzumab-and-zanubrutinib-for-patients-w-nct06563505 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-nct07508995 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-of-zanzalintinib-in-advanced-metastatic-bone-sar-nct07193550 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-2-trial-to-assess-safety-and-efficacy-of-tofacitinib-2-c-nct06698822 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-clinical-study-to-evaluate-hlx43-in-subjects-with-adv-nct06907615 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-evaluation-of-afatinib-in-patients-with-persistent-or-nct02491099 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-open-label-study-of-olutasidenib-post-transplant-main-nct06668584 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-single-center-single-arm-study-evaluating-the-safety-nct06630091 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-evaluating-t-cell-clonality-after-stereotactic-nct05361798 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-axicabtagene-ciloleucel-an-anti-cd19-chimeri-nct06043323 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-loncastuximab-tesirine-as-consolidation-stra-nct05464719 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-pemigatinib-plus-durvalumab-in-previously-tr-nct06728410 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-the-menin-inhibitor-revumenib-in-leukemia-as-nct06229912 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-of-tucatinib-and-ado-trastuzumab-emtansine-t-dm-nct05673928 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-study-with-a-safety-run-in-of-the-addition-of-n-803-t-nct07085338 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-mosunetuzumab-polatuzumab-tafasitamab-and-le-nct05615636 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-sacituzumab-govitecan-in-patients-with-advan-nct06248515 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-trial-of-tebentafusp-in-hla-a-02-01-positive-patients-nct06942442 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-phase-ii-trial-to-evaluate-the-effect-of-itraconazole-on-patho-nct05563766 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-pivotal-phase-ii-clinical-trial-of-utidelone-injection-plus-ca-nct06764940 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compar-nct06992258 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-randomized-study-of-astx727-with-or-without-iadademstat-in-adv-nct06661915 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-randomized-trial-of-fianlimab-and-cemiplimab-ipilimumab-or-ipi-nct07188896 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-randomized-trial-of-maintenance-systemic-therapy-after-radiati-nct06004336 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-single-arm-phase-ii-study-of-neoadjuvant-intensified-androgen-nct05593497 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-single-arm-study-of-pembrolizumab-with-gemcitabine-and-cisplat-nct05967182 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-comparing-two-immunotherapy-options-for-human-papillomav-nct07179315 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-evaluating-ficerafusp-alfa-bca101-qw-in-combination-with-nct07807163 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-evaluating-the-combination-of-immunotherapy-with-radioth-nct07603856 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-evaluating-the-safety-of-inavolisib-and-fulvestrant-with-nct07748208 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-a-new-way-to-treat-children-and-young-adults-with-a-b-nct04684368 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-a-vaccine-in-combination-with-beta-glucan-in-people-w-nct06057948 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-alisertib-in-patients-with-extensive-stage-small-cell-nct06095505 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-amivantamab-in-combination-with-lazertinib-or-amivant-nct06667076 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-amivantamab-in-participants-with-advanced-or-metastat-nct05498428 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-avutometinib-and-defactinib-in-people-with-thyroid-ca-nct06007924 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-avutometinib-defactinib-and-letrozole-in-people-with-nct06394804 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-axicabtagene-ciloleucel-and-glofitamab-as-second-line-nct06213311 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-azenosertib-zn-c3-in-subjects-with-platinum-resistant-nct05128825 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-belzutifan-in-adolescent-participants-with-solid-tumo-nct07700758 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-botensilimab-and-balstilimab-for-colorectal-cancer-wi-nct07227636 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinom-nct06843434 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-cadonilimab-combined-with-chemotherapy-in-people-with-nct07631000 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-combination-chemotherapy-for-patients-with-newly-diag-nct04322318 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-cybord-cyclophosphamide-bortezomib-dexamethasone-plus-nct06083922 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-disitamab-vedotin-alone-or-with-pembrolizumab-in-urot-nct04879329 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-emavusertib-an-approved-bruton-tyrosine-kinase-inhibi-nct07271667 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-enzalutamide-plus-the-glucocorticoid-receptor-antagon-nct05726292 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-fg-3246-in-participants-with-metastatic-castration-re-nct06842498 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-fianlimab-cemiplimab-and-ipilimumab-in-people-with-me-nct06594991 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-imlunestrant-ly3484356-in-premenopausal-women-with-es-nct07287098 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-incb123667-in-participants-with-platinum-resistant-ov-nct07023627 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-investigational-agents-in-participants-with-previousl-nct06780085 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-ivonescimab-in-people-with-endometrial-and-cervical-c-nct06925724 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-ivonescimab-in-people-with-leiomyosarcoma-nct07516925 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-jnj-101556143-in-participants-with-metastatic-prostat-nct07832292 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-jnj-90301900-in-combination-with-chemoradiation-follo-nct06667908 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-jzp3507-onc206-in-recurrent-grade-2-or-3-meningioma-nct07533942 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-lifileucel-tumor-infiltrating-lymphocytes-in-adults-w-nct07741877 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-lower-dose-radiation-therapy-for-people-with-prostate-nct07635238 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-lower-radiotherapy-dose-to-treat-children-with-cns-ge-nct06368817 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-lurbinectedin-in-combination-with-durvalumab-for-the-nct07459634 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-mosunetuzumab-alone-or-with-zanubrutinib-in-people-wi-nct05389293 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-multiple-therapies-in-biomarker-selected-participants-nct04302025 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-nalirifox-in-combination-with-radiation-therapy-in-pe-nct05851924 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-navlimetostat-bms-986504-alone-or-in-combination-with-nct06855771 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-neoadjuvant-amivantamab-with-either-lazertinib-or-che-nct07586202 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-novel-agents-or-combinations-as-perioperative-treatme-nct07069712 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-nuzefatide-pevedotin-bt5528-in-patients-with-metastat-nct07450859 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-nx-5948-in-adults-with-cll-sll-previously-treated-wit-nct07221500 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-obecabtagene-autoleucel-in-people-with-b-cell-acute-l-nct07400029 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-in-people-with-ultra-rare-sarcomas-nct07089992 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-with-or-without-chemotherapy-in-combina-nct06731907 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-pembrolizumab-with-trastuzumab-and-chemotherapy-in-pe-nct06123338 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-pirtobrutinib-venetoclax-and-rituximab-in-people-with-nct07231952 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-response-adapted-ultra-low-dose-4-gy-radiation-for-de-nct05929612 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-sacituzumab-govitecan-immu-132-in-patients-with-recur-nct05838521 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-sasanlimab-palbociclib-and-axitinib-in-metastatic-ren-nct07123090 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-nct05570253 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-selinexor-in-combination-with-carfilzomib-daratumumab-nct04661137 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-selinexor-in-people-with-wilms-tumors-and-other-solid-nct05985161 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-sotorasib-in-people-with-non-small-cell-lung-cancer-nct06582771 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-stereotactic-radiosurgery-srs-and-standard-treatment-nct06741085 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-stereotactic-radiosurgery-srs-for-people-with-lung-ca-nct05419076 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-sync-t-therapy-sv-102-in-participants-with-metastatic-nct06533644 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-t3011-in-patients-with-bcg-unresponsive-nmibc-or-bcg-nct06971614 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-talazoparib-with-or-without-enzalutamide-in-people-wi-nct06844383 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-talquetamab-in-participants-with-relapsed-or-refracto-nct04634552 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-targeted-post-surgery-radiation-therapy-for-non-small-nct07293247 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-tarlatamab-for-people-with-prostate-cancer-nct07111507 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-trk-950-when-used-in-combination-with-ramucirumab-and-nct06038578 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-venetoclax-in-combination-with-conventional-chemother-nct05955261 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-zanzalintinib-in-participants-with-recurrent-or-progr-nct07428616 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-of-zen003694-in-people-with-squamous-cell-lung-cancer-nct05607108 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-testing-the-combination-of-dasatinib-or-imatinib-to-chem-nct06124157 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-change-in-disease-activity-nct07023289 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-change-in-disease-activity-nct07059845 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-and-how-intravenously-iv-infuse-nct06568939 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-adverse-events-change-in-disease-activity-and-nct07744126 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-anti-tumor-activity-of-intravenously-iv-infuse-nct06890338 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-assess-the-efficacy-and-safety-of-fore8394-in-partici-nct05503797 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-compare-the-administration-of-encorafenib-binimetinib-nct04511013 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-estimate-early-clinical-efficacy-signals-of-glp-1-ago-nct07107334 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-efficacy-and-safety-of-ciltacabtagene-autole-nct07149857 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intraveno-nct06820463 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-and-safety-of-belantamab-mafodo-nct07227311 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-and-safety-of-tl118-in-solid-tu-nct06010342 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-efficacy-of-cemsidomide-dexamethasone-in-nct07284758 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-optimal-dose-adverse-events-and-change-i-nct07155174 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-evaluate-the-safety-and-efficacy-of-two-dose-levels-o-nct06948448 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-find-out-if-enfortumab-vedotin-given-with-pembrolizum-nct07475806 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-give-treatment-inside-the-eye-to-treat-retinoblastoma-nct05504291 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-investigate-ubamatamab-with-and-without-marlotamig-re-nct07154290 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-nct06760819 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-see-if-giving-fianlimab-and-cemiplimab-together-is-be-nct06769698 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-test-dsp107-in-combination-with-atezolizumab-in-compa-nct07235293 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-to-test-inavolisib-treatments-in-participants-with-early-nct07054190 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-study-using-nivolumab-in-combination-with-chemotherapy-drugs-t-nct06064097 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-trial-evaluating-the-efficacy-of-ivonescimab-in-metastatic-end-nct07229417 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-trial-of-durvalumab-medi4736-plus-monalizumab-in-non-muscle-in-nct06503614 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/a-ugt1a1-genotype-directed-study-of-belinostat-pharmacokinetics-nct06406465 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/abemaciclib-for-bone-and-soft-tissue-sarcoma-with-cyclin-depende-nct04040205 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/abemaciclib-for-the-treatment-of-recurrent-ovarian-or-endometria-nct04469764 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/abi-pred-adt-vs-adt-in-psma-positive-conventionally-node-negativ-nct07237269 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/abiraterone-enzalutamide-or-apalutamide-in-castrate-sensitive-pr-nct05422911 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/acalabrutinib-in-combination-with-venetoclax-for-the-treatment-o-nct04941716 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/acalabrutinib-lenalidomide-and-rituximab-for-the-treatment-of-cd-nct04404088 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/acalabrutinib-with-da-epoch-r-or-r-chop-for-people-with-untreate-nct04002947 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/acalabrutinib-with-or-without-obinutuzumab-in-treating-patients-nct03516617 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/acoustic-cluster-therapy-act-with-chemotherapy-for-the-treatment-nct06850623 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/act001-for-the-treatment-of-diffuse-intrinsic-pontine-gliomas-an-nct06838676 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ad-hoc-trial-artificial-intelligence-based-drug-dosing-in-hepato-nct05669339 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adaptive-dosing-of-immune-checkpoint-inhibitors-for-hepatocellul-nct07689175 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adaptive-therapy-with-capecitabine-for-treatment-of-metastatic-e-nct06525766 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adding-a-live-biotherapeutic-product-cbm588-to-pembrolizumab-for-nct07037004 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adding-dasatinib-or-venetoclax-to-improve-responses-in-children-nct06390319 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorec-nct06728072 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adjuvant-chemotherapy-and-immunotherapy-for-completely-resected-nct07149363 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adjuvant-ip-001-treatment-for-hcc-patients-following-surgical-re-nct06526338 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/adjuvant-quisinostat-in-high-risk-uveal-melanoma-nct06932757 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/administration-of-autologous-t-cells-genetically-engineered-to-e-nct03412877 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/all-backbone-in-ayas-nct07227584 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/allo-hsct-using-ric-and-ptcy-for-hematological-diseases-nct05805605 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/allosct-for-malignant-and-non-malignant-hematologic-diseases-uti-nct04099966 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/alternate-doses-and-dosing-schedules-of-belantamab-mafodotin-for-nct05847569 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/alternating-chemo-immunotherapy-and-fgfr-inhibitor-for-fgfr-posi-nct07780838 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/an-adjuvant-study-to-evaluate-sms001-paclitaxel-in-non-small-cel-nct06693336 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/an-evaluation-of-maintenance-therapy-combination-mirvetuximab-so-nct05887609 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/androgen-ablation-therapy-with-or-without-niraparib-after-radiat-nct04947254 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/anti-pd-1-mab-plus-metabolic-modulator-in-solid-tumor-malignanci-nct04114136 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/apollo-a-randomized-phase-ii-double-blind-study-of-olaparib-vers-nct04858334 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/asparaginase-erwinia-chrysanthemi-with-chemotherapy-for-the-trea-nct06918431 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/aspen-09-03-a-study-of-evorpacept-in-combination-with-trastuzuma-nct07007559 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/assessment-of-decision-tool-to-select-women-for-gynecologic-spar-nct06184516 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/atempt-2-0-adjuvant-t-dm1-vs-th-nct04893109 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/atezolizumab-and-cabozantinib-for-the-treatment-of-adolescents-a-nct05019703 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/atezolizumab-in-combination-with-a-multi-kinase-inhibitor-for-th-nct05168163 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/atezolizumab-plus-etoposide-and-platinum-in-small-cell-bladder-c-nct05312671 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/autologous-ln-145-in-patients-with-metastatic-non-small-cell-lun-nct04614103 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/azacitidine-and-enasidenib-in-treating-patients-with-idh2-mutant-nct03383575 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/azd0901-in-participants-with-advanced-solid-tumours-expressing-c-nct06219941 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/bal-bot-agent-797-in-pmmr-crc-with-liver-metastases-nct07550088 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-the-trea-nct05208307 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/belzutifan-mk-6482-for-the-treatment-of-advanced-pheochromocytom-nct04924075 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/bicazo-a-study-combining-two-immunotherapies-cabozantinib-and-ni-nct05136196 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/binimetinib-and-imatinib-for-unresectable-stage-iii-iv-kit-mutan-nct04598009 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/binimetinib-for-people-with-relapsed-refractory-braf-wild-type-h-nct04322383 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/biologically-guided-radiation-therapy-bgrt-and-stereotactic-body-nct06014827 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/bladder-preservation-for-patients-with-muscle-invasive-bladder-c-nct06417190 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/bms-986340-in-combination-with-nivolumab-gemcitabine-and-nab-pac-nct07226856 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/brain-metastases-in-greater-size-hypofractionated-options-trial-nct07227610 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/bre-10-biomarker-optimization-of-neoadjuvant-therapy-in-breast-c-nct06441890 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-bendamustine-for-the-treatment-of-relaps-nct04587687 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-nivolumab-for-the-treatment-of-patients-nct04561206 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/brentuximab-vedotin-and-nivolumab-for-the-treatment-of-relapsed-nct05039073 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cabazitaxel-carboplatin-vs-177lu-psma-617-in-metastatic-castrate-nct06738303 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cabozantinib-combined-with-ipilimumab-nivolumab-and-tace-in-pati-nct04472767 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cabozantinib-in-patients-with-ret-fusion-positive-advanced-non-s-nct01639508 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/candida-therapeutic-vaccine-in-head-and-neck-cancer-patients-to-nct05952934 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/captemy90-for-grade-2-3-net-liver-metastases-nct04339036 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/car-t-cell-therapy-in-patients-with-renal-dysfunction-nct05909059 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/carboplatin-taxane-and-ramucirumab-for-patients-with-nsclc-after-nct04332367 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cd22-car-t-cells-to-extend-remission-following-commercial-cd19-c-nct07328503 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cemiplimab-and-cetuximab-prior-salvage-surgery-in-patients-with-nct06448026 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cemiplimab-for-the-treatment-of-incurable-metastatic-or-unresect-nct07050186 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cemiplimab-plus-gemcitabine-in-patients-with-metastatic-pancreat-nct06790602 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cetuximab-after-immunotherapy-for-the-treatment-of-head-and-neck-nct04375384 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/chemotherapy-anakinra-in-patients-with-pancreatic-adenocarcinoma-nct04926467 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/chemotherapy-and-radiation-therapy-for-the-treatment-of-idh-wild-nct04623931 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/chemotherapy-with-or-without-immunotherapy-for-peritoneal-mesoth-nct05001880 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/chemotherapy-with-or-without-radiation-or-surgery-in-treating-pa-nct03161522 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/circulating-tumor-dna-nct06923527 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/circulating-tumor-dna-to-guide-changes-in-standard-of-care-chemo-nct05770531 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cladribine-and-rituximab-in-treating-patients-with-hairy-cell-le-nct00412594 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/clag-go-for-patients-with-persistent-relapsed-or-refractory-aml-nct04050280 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cobimetinib-in-refractory-langerhans-cell-histiocytosis-lch-and-nct04079179 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/combination-chemotherapy-in-treating-patients-with-relapsed-or-r-nct03136146 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/combination-therapy-for-the-treatment-of-diffuse-midline-gliomas-nct05009992 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/combination-therapy-using-durvalumab-and-histotripsy-for-treatme-nct07766187 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/combined-systemic-and-intraperitoneal-chemotherapy-for-synchrono-nct07475286 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/comparing-cytarabine-daunorubicin-therapy-versus-cytarabine-daun-nct05554393 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/comparing-different-treatment-lengths-for-venetoclax-in-older-pe-nct07437950 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/comparing-new-treatments-for-people-with-newly-diagnosed-acute-m-nct06672146 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/comparing-the-effectiveness-of-the-immunotherapy-agents-rituxima-nct05886036 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/comparing-the-radiopharmaceutical-drug-177lu-lu-dotatate-to-stan-nct06955169 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/concurrent-immunotherapy-and-systemic-therapy-with-stereotactic-nct07770100 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/consolidation-of-first-line-mrd-remission-with-cema-cel-in-patie-nct06500273 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/consolidative-local-therapy-clt-in-oligo-metastatic-urothelial-c-nct07048457 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cord-blood-transplant-cyclophosphamide-fludarabine-and-total-bod-nct06013423 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cpx-351-and-ivosidenib-for-the-treatment-of-idh1-mutated-acute-m-nct04493164 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cryoablation-ipilimumab-nivolumab-in-melanoma-nct05779423 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ctdna-guided-addition-of-ipilimumab-to-patients-receiving-nivolu-nct07504796 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ctdna-guided-sunitinib-and-regorafenib-therapy-for-gist-nct05366816 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ctdna-guided-therapy-for-relapsed-refractory-hodgkin-lymphoma-nct07021989 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-nct07425054 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/cyclophosphamide-and-sirolimus-for-the-treatment-of-metastatic-r-nct03099356 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dabrafenib-and-trametinib-for-braf-v600-mutant-low-grade-gliomas-nct07110246 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/daly-ii-usa-mb-cart2019-1-for-dlbcl-nct04792489 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/daratumumab-for-chemotherapy-refractory-minimal-residual-disease-nct05289687 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/daratumumab-for-relapsed-refractory-primary-effusion-lymphoma-pl-nct05907759 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dareontm-5-a-study-to-test-whether-different-doses-of-bi-764532-nct05882058 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dasatinib-and-quercetin-with-car-t-therapy-for-the-treatment-of-nct06940297 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dato-base-datopotamab-deruxtecan-for-breast-cancer-brain-metasta-nct06176261 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dcis-recast-trial-ductal-carcinoma-in-situ-re-evaluating-conditi-nct06075953 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/decitabine-cedazuridine-inqovi-an-oral-dna-demethylating-agent-i-nct05960773 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/decitabine-with-ruxolitinib-fedratinib-or-pacritinib-for-the-tre-nct04282187 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/defining-the-ablative-dose-for-y-90-tare-nct07586046 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dfmo-as-maintenance-therapy-for-molecular-high-very-high-risk-an-nct04696029 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/digoxin-medulloblastoma-study-nct06701812 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/discern-dual-versus-single-icb-in-pdl-1-negative-nsclc-nct06364917 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/doc1021-dendritic-cell-immunotherapy-for-treatment-of-newly-diag-nct06805305 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/dose-adjusted-epoch-with-or-without-rituximab-plus-ponatinib-for-nct07224100 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/durvalumab-in-combination-with-chemotherapy-in-treating-patients-nct03907475 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/duvelisib-maintenance-for-the-treatment-of-peripheral-t-cell-lym-nct07293403 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/e7-tcr-t-cell-immunotherapy-for-human-papillomavirus-hpv-associa-nct05686226 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/effects-of-infusion-timing-on-treatment-response-in-solid-tumors-nct07630168 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/efficacy-and-safety-of-nemtabrutinib-mk-1026-in-participants-wit-nct04728893 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/efficacy-and-safety-of-tyra-300-in-participants-with-fgfr3-alter-nct06995677 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/efficacy-of-hypomethylating-agents-vs-intensive-chemotherapy-in-nct07060001 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/elranatamab-in-r-r-multiple-myeloma-nct06138275 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/enasidenib-and-azacitidine-in-treating-patients-with-recurrent-o-nct03683433 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/enasidenib-in-idh2-mutated-malignant-sinonasal-and-skull-base-tu-nct06176989 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/endocrine-treatment-alone-for-elderly-patients-with-estrogen-rec-nct02476786 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/enfortumab-vedotin-with-or-without-pembrolizumab-in-rare-genitou-nct06041503 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/enzalutamide-and-pds01adc-in-pet-positive-recurrent-prostate-can-nct06096870 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/epco-zanu-ritux-for-r-r-fl-or-mzl-nct06563596 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/epcoritamab-and-lenalidomide-in-treating-patients-with-refractor-nct06723457 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/epcoritamab-in-combination-with-loncastuximab-tesirine-in-relaps-nct06919939 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/epcoritamab-rituximab-gemcitabine-and-oxaliplatin-r-gemox-as-sal-nct07365306 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/epcoritamab-with-dose-adjusted-etoposide-cyclophosphamide-vincri-nct07097363 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/estrogen-to-improve-quality-of-life-for-men-with-newly-diagnosed-nct07466498 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ethan-et-for-male-bc-nct05501704 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/eus-rfa-pancardinal-1-trial-nct04990609 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluate-optimization-of-crs-profile-for-glofit-monotherapy-and-nct06806033 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluating-a-decreased-dose-of-radiation-therapy-to-the-elective-nct07178301 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluating-efficacy-of-b7-h3-car-t-cells-administered-at-the-end-nct07428993 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluation-of-alternative-site-goserelin-acetate-injection-for-o-nct07460752 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluation-of-mirvetuximab-soravtansine-imgn853-in-women-with-fo-nct03832361 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-m-nct06607458 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-m-nct06875128 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/evaluation-of-two-dose-levels-of-quizartinib-as-maintenance-in-f-nct06824168 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/exclaim-exploring-combined-local-and-systemic-approaches-in-brai-nct06649058 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/extracorporeal-photopheresis-and-mogamulizumab-for-the-treatment-nct04930653 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/fdg-pet-guided-metastasis-directed-radiation-therapy-for-the-tre-nct06244004 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/feasibility-study-to-treat-lung-cancer-with-the-permanently-impl-nct03290534 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/fludarabine-phosphate-cytarabine-filgrastim-sndz-gemtuzumab-ozog-nct00801489 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/fluorescence-guided-surgical-resection-for-reducing-unexpected-p-nct07650656 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/focal-therapy-with-stereotactic-body-radiation-therapy-sbrt-for-nct05616650 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/folate-receptor-alpha-dendritic-cells-fr-dcs-or-placebo-for-the-nct06639074 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-li-nct07446322 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/folfox-botensilimab-and-balstilimab-for-the-treatment-of-localiz-nct06780787 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/fractionated-gemtuzumab-ozogamicin-in-treating-measurable-residu-nct03737955 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/frameless-stereotactic-radiosurgery-for-intact-brain-metastases-nct02747303 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/functional-precision-oncology-to-predict-prevent-and-treat-early-nct05464082 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/futibatinib-in-combination-with-durvalumab-prior-to-cystectomy-f-nct06263153 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gemcitabine-and-oxaliplatin-chemotherapy-with-or-without-a-floxu-nct04891289 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gemcitabine-cisplatin-and-nab-paclitaxel-as-neoadjuvant-treatmen-nct06423326 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gemcitabine-docetaxel-toripalimab-induction-in-epstein-barr-viru-nct06592599 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gemcitabine-nab-paclitaxel-plus-the-therabionic-p1-an-amplitude-nct06576115 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/genetic-testing-to-select-therapy-for-the-treatment-of-advanced-nct05361720 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/genomic-biomarker-selected-umbrella-neoadjuvant-study-for-high-r-nct04812366 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/genomically-guided-radiation-therapy-in-the-management-of-triple-nct05528133 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gi-102-alone-or-with-pembrolizumab-before-surgery-for-treatment-nct07301268 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/glioblastoma-temozolomide-with-or-without-wsd0922-fu-nct07708961 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/glofitamab-with-pirtobrutinib-for-relapsed-or-refractory-mantle-nct06252675 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/glory-glofit-gemox-with-liso-cel-for-lymphoma-nct07711483 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/golcadomide-and-rituximab-as-bridging-therapy-for-relapsed-or-re-nct06834373 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/graft-versus-host-disease-reduction-strategies-for-donor-blood-s-nct03970096 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/gt103-in-combination-with-pembrolizumab-for-the-treatment-of-adv-nct07017829 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/haplo-identical-transplantation-for-severe-aplastic-anemia-hypo-nct03520647 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/haploidentical-donor-cytokine-induced-memory-like-natural-killer-nct07635056 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hcmt-mm2401-ph2-study-of-selinexor-bispecific-antibody-for-rrmm-nct06822972 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/herizon-breast-a-ctdna-guided-adaptive-study-of-sequential-anti-nct07459673 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/high-dose-ruxolitinib-and-allogeneic-stem-cell-transplantation-i-nct06345495 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/high-dose-testosterone-for-atm-cdk12-or-chek2-altered-prostate-c-nct05011383 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hippocampal-avoidance-in-craniospinal-irradiation-for-the-treatm-nct06518057 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hormone-therapy-apalutamide-and-image-guided-stereotactic-body-r-nct06067269 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hotspot-stereotactic-ablative-radiotherapy-versus-traditional-st-nct07718672 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hypofractionated-radiation-therapy-for-merkel-cell-carcinoma-nct05100095 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/hypofractionated-radiochemotherapy-nct06331468 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/iberdomide-and-daratumumab-as-maintenance-therapy-after-an-autol-nct06107738 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/identifying-effective-and-cost-conscious-maintenance-daratumumab-nct07485647 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/idh-targeted-non-targeted-vs-non-targeted-idh-targeted-approache-nct05401097 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/igfbp-2-vaccine-to-prevent-ovarian-cancer-progression-in-patient-nct07495124 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/iit2023-09-chung-upfronttad-upfront-tad-snb-in-patients-with-bre-nct06092892 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ilkn421h-plus-pembrolizumab-in-advanced-non-small-cell-lung-canc-nct07452224 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/illuminate-a-clinical-study-evaluating-car-t-immune-cell-therapy-nct07680439 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/imlunestrant-and-abemaciclib-for-the-treatment-of-estrogen-recep-nct07191717 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunoplant-for-newly-diagnosed-multiple-myeloma-nct06376526 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunotherapy-and-nodal-sparing-irradiation-for-t-cell-induction-nct07773987 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunotherapy-biomarkers-to-predict-first-line-pd-l-1-based-immu-nct07288034 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunotherapy-platform-study-in-platinum-resistant-high-grade-se-nct04918186 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunotherapy-toripalimab-for-reducing-recurrence-risk-after-sur-nct07140679 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-nct01174121 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/impact-of-vitamin-d-supplementation-on-the-rate-of-pathologic-co-nct04677816 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/individualized-screening-trial-of-innovative-glioblastoma-therap-nct02977780 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/innovative-trial-for-understanding-the-impact-of-targeted-therap-nct04374305 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/inobrodib-pomalidomide-and-dexamethasone-in-relapsed-or-refracto-nct07096778 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/inotuzumab-ozogamicin-and-blinatumomab-with-or-without-ponatinib-nct03739814 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/intensity-modulated-total-marrow-irradiation-in-fully-human-leuk-nct06802315 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/interleukin-6-receptor-inhibitor-sarilumab-in-combination-with-i-nct05428007 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/intermittent-fasting-using-a-fasting-mimicking-diet-to-improve-p-nct05832086 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/intralesional-chemotherapy-ic-cisplatin-epinephrine-nct07392580 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/investigation-of-ubamatamab-combination-therapy-in-adult-partici-nct06787612 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivonescimab-alone-and-with-carboplatin-pemetrexed-for-nsclc-nct07405190 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivonescimab-before-surgery-for-the-treatment-of-resectable-stage-nct07094685 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivonescimab-for-the-treatment-of-thymic-cancer-nct06980077 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivonescimab-in-comb-with-folfox-in-advanced-her2-neg-gea-nct07070466 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivonescimab-prior-to-surgery-for-the-treatment-of-high-risk-loca-nct07226544 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ivosidenib-as-post-hsct-maintenance-for-aml-nct06707493 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/keymaker-u01-substudy-01j-a-study-of-pembrolizumab-plus-mk-1084-nct07252739 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/kqb198-in-combination-with-imatinib-in-participants-with-advance-nct07406633 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/l19il2-l19tnf-in-patients-with-cutaneous-squamous-cell-carcinoma-nct07228442 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/l19il2-tnf-in-patients-with-basal-cell-carcinoma-nct07227870 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/lerapolturev-pvsripo-in-gbm-nct06177964 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/letrozole-in-uterine-leiomyosarcoma-nct05649956 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/leuprolide-and-goserelin-for-ovarian-function-suppression-in-pre-nct07158021 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-wi-nct05854498 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/liposome-encapsulated-daunorubicin-cytarabine-and-venetoclax-in-nct03629171 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/liquid-nitrogen-spray-cryotherapy-prior-to-neoadjuvant-systemic-nct07222657 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/local-consolidative-therapy-and-durvalumab-for-oligoprogressive-nct04892953 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/loncastuximab-tesirine-and-mosunetuzumab-for-the-treatment-of-re-nct05672251 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/loncastuximab-tesirine-and-rituximab-as-bridging-therapy-before-nct06788964 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/low-dose-mosunetuzumab-for-the-treatment-of-patients-with-indole-nct06442475 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/low-psma-suv-boost-lps-boost-intensified-177lu-psma-617-treatmen-nct06526299 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/lu-177-dotatate-lutathera-in-therapy-of-inoperable-pheochromocyt-nct03206060 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/luminal-bladder-cancer-effective-response-to-neoadjuvant-chemoth-nct07762586 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/lurbinectedin-with-or-without-avelumab-in-small-cell-carcinoma-o-nct06228066 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/lutathera-for-the-treatment-of-inoperable-progressive-meningioma-nct04082520 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/maintenance-combinatorial-myeloid-immunotherapy-for-unresectable-nct07199764 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/maintenance-niraparib-plus-ipilimumab-in-patients-with-metastati-nct06747845 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/maintenance-obinutuzumab-in-treating-patients-with-central-nervo-nct06175000 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/marginal-zone-lymphoma-nemtabrutinib-and-rituximab-nct07583810 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mavric-studies-2l-treatment-with-av-in-patients-with-cll-sll-who-nct07024706 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mdrt-in-prostate-cancer-treated-with-long-term-androgen-deprivat-nct06150417 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/measurable-residual-disease-guided-post-transplant-elranatamab-m-nct06483100 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/metformin-hydrochloride-in-combination-with-standard-of-care-sys-nct07291297 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-muc-nct07693452 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/methylprednisolone-horse-anti-thymocyte-globulin-cyclosporine-fi-nct01624805 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/metronomic-decitabine-cedazuridine-and-venetoclax-in-r-r-aml-hr-nct07710534 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/metronomic-gemcitabine-mitomycin-c-and-thalidomide-for-advanced-nct07671534 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mezigdomide-carfilzomib-and-dexamethasone-for-the-treatment-of-r-nct06627751 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mogamulizumab-low-dose-total-skin-electron-beam-tx-in-mycosis-fu-nct04256018 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/molecular-analyses-to-predict-pathways-of-endocrine-resistance-f-nct06361940 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/molecular-and-clinical-risk-directed-therapy-for-infants-and-you-nct05535166 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/monthly-alternating-nalirifox-and-gnp-in-the-first-line-setting-nct07163273 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mosunetuzumab-and-polatuzumab-vedotin-for-the-treatment-of-patie-nct06453044 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mosunetuzumab-and-polatuzumab-vedotin-with-split-dose-chp-chemot-nct06594939 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mosunetuzumab-with-lenalidomide-augmentation-as-first-line-thera-nct04792502 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mri-based-focal-intraprostatic-simultaneous-integrated-boost-sib-nct07644598 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/mt2022-60-ph-2-study-of-pembro-beam-with-asct-for-relapsed-hodgk-nct06377540 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/myeloablative-consolidation-therapy-and-tandem-autologous-stem-c-nct02605421 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nalirifox-before-surgery-for-the-treatment-of-borderline-resecta-nct06821997 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nant-2021-01-phase-ii-sting-sequential-temozolomide-irinotecan-n-nct06450041 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/naxitamab-added-to-induction-for-newly-diagnosed-high-risk-neuro-nct05489887 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nemtabrutinib-and-lisocabtagene-maraleucel-for-the-treatment-of-nct07194980 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nemtabrutinib-and-pembrolizumab-for-the-treatment-of-richter-tra-nct06863402 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nemtabrutinib-and-venetoclax-for-the-treatment-of-patients-with-nct07557056 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nemtabrutinib-with-car-t-therapy-in-relapsed-refractory-mantle-c-nct07673367 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-and-adjuvant-treatment-in-resectable-non-small-cell-nct05061550 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-botensilimab-and-balstilimab-for-the-treatment-of-ad-nct07595874 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-chemo-immunotherapy-and-surgical-resection-in-locall-nct06449313 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-chemotherapy-for-borderline-resectable-and-locally-a-nct05825066 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-folfirinox-combined-with-pembrolizumab-followed-by-s-nct05132504 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-inbrx-106-in-combination-with-pembrolizumab-for-stag-nct06353997 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-lenvatinib-and-pembrolizumab-for-ivc-tumor-thrombus-nct05319015 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-neratinib-in-stage-i-iii-her2-mutated-lobular-breast-nct05919108 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-pembrolizumab-and-porustobart-in-resectable-pmmr-mss-nct07808151 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-spare-adjuvant-nasa-in-stage-iiib-iv-m1a-melanoma-nct07740941 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-tebentafusp-for-uveal-melanoma-nct06414590 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/neoadjuvant-zanzalintinib-plus-nivolumab-in-patients-with-locall-nct06794229 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/newly-diagnosed-stage-iii-iv-ovarian-cancer-neoadjuvant-carbo-ta-nct05952453 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nirogacestat-in-patients-with-kaposi-sarcoma-nct07539454 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nivolumab-in-epstein-barr-virus-ebv-positive-lymphoproliferative-nct03258567 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/nodal-radiation-therapy-for-sentinel-lymph-node-positive-melanom-nct04594187 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/obinutuzumab-and-ice-chemotherapy-in-refractory-recurrent-cd20-m-nct02393157 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/odronextamab-for-relapsed-and-refractory-large-b-cell-lymphomas-nct06784726 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/olaparib-with-cediranib-or-azd6738-for-the-treatment-of-advanced-nct04090567 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/olutasidenib-in-relapsed-idh1-mutated-aml-patients-who-have-prev-nct07471841 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/olutasidenib-with-azacitidine-followed-by-olutasidenib-maintenan-nct07304011 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/open-label-of-loncastuximab-tesirine-adct-402-in-relapsed-refrac-nct05296070 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combin-nct06369259 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/optimal-psa-triggered-individual-management-of-androgen-sensitiv-nct07216248 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/optimizing-neurocognition-with-whole-brain-radiation-therapy-wbr-nct05045950 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/oral-tgf-beta-receptor-i-inhibitor-vactosertib-in-soc-chemoradio-nct06044311 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/osimertinib-alone-or-with-chemotherapy-for-egfr-mutant-lung-canc-nct04410796 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/osimertinib-and-cyclosporine-a-to-enhance-antitumor-efficacy-in-nct07874490 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/oxaliplatin-and-liposomal-irinotecan-plus-trastuzumab-for-her2-p-nct04150640 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pacritinib-in-participants-with-metastatic-castrate-resistant-pr-nct07226713 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pacritinib-vs-hydroxyurea-in-advanced-proliferative-chronic-myel-nct07033598 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/palbociclib-and-pembrolizumab-in-central-nervous-system-metastas-nct02896335 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pancreatic-cancer-choose-preoperative-chemotherapy-by-smad4-stat-nct07748611 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/paxalisib-gdc-0084-in-recurrent-or-refractory-pcnsl-nct04906096 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pbi-11-ta-hpv-with-pembrolizumab-as-treatment-for-patients-w-adv-nct05799144 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pd-l1-t-hank-nai-il-15sa-and-cetuximab-for-recurrent-metastatic-nct06239220 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pds01adc-in-combination-with-hepatic-artery-infusion-pump-haip-a-nct05286814 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembro-with-radiation-with-or-without-olaparib-nct05568550 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-and-enfortumab-vedotin-with-pembrolizumab-prior-to-nct05775471 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-and-hypofractionated-radiation-therapy-for-the-tre-nct04318717 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-and-lenvatinib-in-advanced-cervical-cancer-nct04865887 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-and-lenvatinib-in-mismatch-repair-proficient-recur-nct07594015 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-and-odetiglucan-in-liver-predominant-metastatic-co-nct07082439 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-combined-with-bevacizumab-with-or-without-agonist-nct05231122 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-in-combination-with-chemotherapy-for-the-treatment-nct07275216 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-n-803-alone-or-in-combination-with-pd-l1-t-hank-ce-nct06161545 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-olaparib-and-temozolomide-for-people-with-glioma-nct05188508 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pembrolizumab-plus-177lu-psma-617-in-patients-with-castration-re-nct05766371 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pemetrexed-response-in-relation-to-tumor-alterations-of-gene-sta-nct06630416 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pep-cmv-vaccine-targeting-cmv-antigen-to-treat-newly-diagnosed-p-nct05096481 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/personalized-neck-radiation-therapy-directed-by-sentinel-lymph-n-nct07121595 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/personalized-reduction-of-chemotherapy-intensity-through-ctdna-e-nct06745076 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pet-dynamics-to-response-adapted-neoadjuvant-therapy-in-tnbc-nct06245889 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ph-ii-intraperitoneal-paclitaxel-system-therapy-in-gi-ca-w-perit-nct07795749 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-single-arm-rectal-cancer-brachytherapy-for-patients-with-nct07292298 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-assessing-the-clinical-activity-and-safety-of-obec-nct07053059 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-of-combination-tivozanib-and-nivolumab-in-advanced-nct06053658 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-of-glofitamab-monotherapy-with-polatuzumab-vedotin-nct06043674 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-of-mosunetuzumab-in-patients-with-chronic-lymphocy-nct07566364 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-b-nct06589440 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-study-to-evaluate-safety-and-efficacy-of-cretostimogene-nct06567743 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-trial-of-epcoritamab-in-combination-with-rituximab-mini-nct06045247 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-trial-of-lisocabtagene-maraleucel-for-minimal-residual-d-nct07316010 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-trial-of-obinutuzumab-and-cc-99282-for-patients-with-pre-nct06108232 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-2-trial-of-zanzalintinib-and-pembrolizumab-in-select-subty-nct07283731 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-decentralized-pragmatic-trial-of-adjuvant-doxorubicin-t-nct07076186 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-protocol-of-proton-therapy-for-partial-breast-irradiati-nct01766297 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-assessing-efficacy-and-safety-of-asciminib-in-pat-nct06236724 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-assessing-the-safety-and-efficacy-of-dasatinib-in-nct07269470 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-asciminib-for-second-line-treatment-of-chronic-nct06629584 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-nivolumab-plus-avd-in-pediatric-adolescent-and-nct07551583 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-peptide-receptor-radionuclide-therapy-in-combi-nct05583708 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-platinum-etoposide-plus-ivonescimab-for-extens-nct07057791 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-second-line-pembrolizumab-plus-gvd-for-relapse-nct03618550 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-study-of-the-effects-of-laparoscopic-hyperthermic-intra-nct04107077 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-comparison-of-3-vs-4-fractions-brachy-fit-nct07022470 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-combination-anti-pd-1-and-aldesleukin-for-meta-nct05155033 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-ivonescimab-in-combination-with-carboplatin-do-nct07017673 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-ivonescimab-in-previously-treated-patients-wit-nct06940518 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-neoadjuvant-chemotherapy-nac-alone-or-in-combi-nct06223568 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-psa-response-based-androgen-deprivation-therap-nct07313241 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-puxitatug-samrotecan-azd8205-in-advanced-recur-nct07162480 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-sacituzumab-govitecan-in-recurrent-and-or-meta-nct05884320 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/phase-ii-trial-of-sacituzumab-tirumotecan-in-patients-with-smarc-nct07438626 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pilot-study-of-ivonescimab-in-advanced-metastatic-cutaneous-angi-nct07655570 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pilot-trial-of-fecal-microbiota-transplantation-for-lymphoma-pat-nct06218602 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pirtobrutinib-for-the-treatment-of-elderly-patients-with-chronic-nct07685717 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/post-autologous-transplant-maintenance-with-isatuximab-and-lenal-nct05344833 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/post-transplant-maintenance-therapy-with-isatuximab-plus-lenalid-nct05776979 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pre-operative-atezolizumab-in-patients-with-resectable-human-pap-nct06254911 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pre-radiation-chemotherapy-for-newly-diagnosed-high-grade-glioma-nct07439172 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pre-transplant-purging-and-post-transplant-mrd-guided-maintenanc-nct06207799 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/precision-medicine-in-action-phase-ii-trial-of-response-adaptive-nct06444269 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/preoperative-pembrolizumab-and-chemotherapy-in-resectable-recurr-nct05726370 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/preoperative-radiotherapy-and-immunotherapy-for-sinonasal-and-an-nct05546827 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/propranolol-with-chemotherapy-or-chemoradiation-for-esophageal-a-nct04682158 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/prorad-5-prostate-radiation-in-5-fractions-phase-ii-five-fractio-nct06369246 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/prospective-trial-assessing-real-world-outcomes-response-to-pemb-nct06745882 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/prostate-cancer-treatment-using-androgen-deprivation-therapy-and-nct05790213 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/prostate-specific-membrane-antigen-psma-or-facbc-pet-ct-site-dir-nct04175431 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/protocol-number-hjkc3-0003-treatment-free-remission-after-ascimi-nct04838041 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/proton-beam-radiation-therapy-after-treatment-for-resected-n2-no-nct06008730 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/proton-radiation-for-unresectable-borderline-resectable-or-medic-nct02598349 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/proton-therapy-for-post-surgical-treatment-of-gynecologic-cancer-nct05758688 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/psma-directed-para-aortic-radiation-therapy-for-oligorecurrent-p-nct06392295 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/psma-pet-guided-de-escalation-of-salvage-radiation-treatment-in-nct07234981 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pt-112-in-subjects-with-thymoma-and-thymic-carcinoma-nct05104736 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/pulso-trial-pulsed-low-dose-rate-pldr-radiation-chemoradiation-c-nct06906887 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/radiation-and-tsr-042-dostarlimab-in-people-with-endometrial-can-nct04774419 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/radiation-prior-to-tki-to-delay-progression-in-advanced-driver-m-nct06305715 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/radiation-therapy-approaches-for-people-with-prostate-cancer-nct07751159 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/radiation-therapy-with-or-without-cisplatin-in-treating-patients-nct02734537 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/radiotherapy-in-combination-with-checkpoint-inhibition-for-patie-nct06601296 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ramucirumab-and-paclitaxel-or-folfiri-in-advanced-small-bowel-ca-nct04205968 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/rapid-analysis-and-response-evaluation-of-combination-anti-neopl-nct04449549 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/real-time-mri-guided-3-fraction-accelerated-partial-breast-irrad-nct03936478 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/recombinant-glycosylated-human-interleukin-7-cyt107-for-the-trea-nct07308886 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/rectify-1-neoadjuvant-botensilimab-balstilimab-in-mss-pmmr-early-nct07735624 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/recurrent-ovarian-cancers-after-parp-maintenance-sacituzumab-gov-nct07504588 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/regorafenib-reg-and-lorigerlimab-lor-relo-regimen-in-treatment-o-nct07071961 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/regulus-mri-guided-adaptive-sabr-for-liver-cancers-nct07223307 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/relacorilant-in-combination-with-different-treatment-regimens-in-nct06906341 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/relacorilant-with-nab-paclitaxel-and-gemcitabine-in-patients-wit-nct07259317 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/repeat-breast-conserving-surgery-followed-by-daily-partial-breas-nct06129747 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/repurposing-atovaquone-for-the-treatment-of-platinum-resistant-o-nct05998135 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/resectable-lung-cancer-cemiplimab-and-fianlimab-before-surgery-nct06918132 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/restoring-lymphocytes-using-nktr-255-after-chemoradiotherapy-in-nct05632809 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ribociclib-and-endocrine-treatment-of-physicians-choice-for-loco-nct05467891 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/risk-adapted-proteomic-guided-systemic-therapy-for-previously-un-nct07250477 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/risk-adapted-therapy-in-hpv-oropharyngeal-cancer-using-circulati-nct04900623 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/rituximab-and-zanubrutinib-in-patients-with-indolent-b-cell-lymp-nct06350318 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ruxolitinib-before-during-and-after-hematopoietic-cell-transplan-nct07228624 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ruxolitinib-for-the-treatment-of-t-cell-large-granular-lymphocyt-nct05592015 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ruxolitinib-maintenance-post-hematopoietic-stem-cell-transplant-nct07356245 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ruxolitinib-with-radiation-and-temozolomide-compared-to-radiatio-nct06991101 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sacituzumab-govitecan-with-or-without-atezolizumab-immunotherapy-nct06161532 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/safety-and-efficacy-study-of-intravesical-instillation-of-tara-0-nct05951179 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/safety-and-efficacy-study-of-safusidenib-in-participants-with-id-nct07703436 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/selinexor-and-pacritinib-in-jak-inhibitor-nai-ve-mf-patients-wit-nct07447817 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/selpercatinib-pre-rai-in-patients-with-ret-fusion-thyroid-cancer-nct06458036 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sequencing-antibody-drug-conjugates-in-er-her2-low-ultra-low-mbc-nct06263543 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sequential-testosterone-and-enzalutamide-prevents-unfavorable-pr-nct04363164 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sequential-treatment-of-cabozantinib-for-advanced-renal-cell-car-nct05931393 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sfolfoxiri-in-advanced-gastroesophageal-cancer-sage-nct05332002 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/short-course-adt-for-high-risk-low-intermediate-risk-artera-pros-nct07801664 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/shortening-adjuvant-photon-and-proton-irradiation-sapphire-ii-a-nct07076485 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/single-arm-study-of-neoadjuvant-dostarlimab-in-stage-ii-and-iii-nct05239546 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/single-fraction-interstitial-breast-brachytherapy-nct07654257 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/smarca4-2-inhibitor-for-pou2f3-positive-sclc-nct07551635 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/srs-compared-with-fsrs-for-treatment-of-intact-metastatic-brain-nct05222620 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/statins-in-patients-with-clonal-cytopenia-of-undetermined-signif-nct05483010 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/stereotactic-body-radiation-therapy-plus-immediate-or-delayed-an-nct06378866 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/stereotactic-brain-directed-radiation-with-or-without-aguix-gado-nct04899908 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/stereotactic-radiation-for-growing-changing-brain-metastases-wit-nct07132190 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/strategic-endocrine-therapy-and-targeted-radiotherapy-for-prosta-nct07364071 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-adding-drugs-to-usual-treatment-for-large-b-cell-lymphoma-nct05890352 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-evaluating-dosimetry-randomized-dose-optimization-dose-esc-nct06549465 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-ar-suppression-with-carotuximab-in-metastatic-castratio-nct05534646 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-belantamab-mafodotin-with-carfilzomib-pomalidomide-and-nct05789303 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-bevacizumab-in-combination-with-chemoimmunotherapy-and-nct05588388 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-carboplatin-and-mirvetuximab-soravtansine-in-first-line-nct04606914 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-cryoablation-and-nirogacestat-for-desmoid-tumor-nct05949099 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-denikitug-gs-1811-given-alone-or-with-nivolumab-or-chem-nct07546812 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-denikitug-gs-1811-given-alone-or-with-nivolumab-or-with-nct07527858 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-ev-for-recurrent-endometrial-carcinoma-nct07139977 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-induction-pd-1-blockade-in-subjects-with-locally-advanc-nct04165772 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-kte-x19-in-minimal-residual-disease-mrd-positive-b-cell-nct06144606 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-nalirifox-in-advanced-unresectable-small-bowel-tumors-nct06835387 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-olutasidenib-and-temozolomide-in-hgg-nct06161974 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-onc206-jzp3507-in-advanced-pheochromocytoma-and-paragan-nct07282587 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-oral-mrt-2359-with-apalutamide-in-prostate-cancer-nct07745361 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-patritumab-deruxtecan-plus-pembrolizumab-with-other-ant-nct06797635 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-pembrolizumab-carboplatin-paclitaxel-and-radiation-for-nct06493019 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-ruxolitinib-in-relapsed-or-refractory-t-or-nk-cell-lymp-nct02974647 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-silevertinib-with-temozolomide-for-the-treatment-of-new-nct07326566 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-of-the-efficacy-of-intratumoral-l19il2-or-l19tnf-or-l19il2-nct06284590 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-to-assess-the-efficacy-and-safety-of-rina-s-in-participant-nct07288177 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-to-determine-the-efficacy-and-safety-of-asciminib-in-pedia-nct07354074 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-to-evaluate-sutetinib-maleate-capsule-in-locally-advanced-nct05168566 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/study-to-evaluate-the-safety-and-tolerability-of-camizestrant-in-nct07427394 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/subcutaneous-talquetamab-in-elderly-patients-with-multiple-myelo-nct06827860 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/substudy-01i-a-study-of-investigational-agents-in-participants-w-nct06780098 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/suprachoroidal-administration-in-subjects-with-metastases-to-the-nct06643884 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/supraphysiological-androgen-to-enhance-treatment-activity-in-met-nct06039371 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/surovatamig-azd0486-as-monotherapy-in-participants-with-relapsed-nct06526793 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sx-682-and-atezolizumab-for-the-treatment-of-advanced-or-metasta-nct07322341 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/sx-682-with-pembrolizumab-for-the-treatment-of-metastatic-or-rec-nct05570825 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/t-cell-receptor-immunotherapy-for-patients-with-metastatic-non-s-nct02133196 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/tafasitamab-and-rituximab-for-the-treatment-of-newly-diagnosed-f-nct07731789 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/tagraxofusp-and-azacitidine-with-venetoclax-in-newly-diagnosed-s-nct05442216 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/tapur-testing-the-use-of-food-and-drug-administration-fda-approv-nct02693535 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/targeted-treatment-for-advanced-non-small-cell-lung-cancer-that-nct06116682 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/tarlatamab-for-the-treatment-of-extensive-stage-small-cell-lung-nct07423585 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/tebentafusp-in-hla-a-0201-positive-previously-untreated-metastat-nct06070012 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-an-experimental-approach-to-treat-patients-with-plasma-c-nct07605416 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-atezolizumab-with-selinexor-in-people-12-years-old-with-nct05333458 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-drug-treatments-after-car-t-cell-therapy-in-patients-wit-nct05633615 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-new-therapies-for-patients-with-acute-myeloid-leukemia-w-nct05554406 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-nivolumab-with-or-without-ipilimumab-in-deficient-mismat-nct05112601 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-of-bevacizumab-erlotinib-and-atezolizumab-in-combination-nct04981509 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-osimertinib-as-a-treatment-for-lung-cancers-with-an-egfr-nct03191149 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-anti-cancer-drug-cabozantinib-to-the-nct06900595 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-idh2-inhibitor-enasidenib-to-usual-tr-nct06577441 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-an-individualized-vaccine-to-durvalumab-nct03606967 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-bms-986016-relatlimab-to-the-usual-immun-nct06029270 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-cemiplimab-regn2810-to-chemotherapy-trea-nct07281417 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-t-nct07195734 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-immunotherapy-before-surgery-for-patient-nct05647265 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-stereotactic-radiation-therapy-with-immu-nct05327686 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-the-anti-cancer-drug-venetoclax-and-or-t-nct06317662 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-the-immunotherapy-drug-pembrolizumab-to-nct06770582 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-addition-of-venetoclax-or-gemtuzumab-ozogamicin-go-t-nct06917911 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-anti-cancer-drug-glofitamab-in-patients-with-mantle-nct07003295 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-combination-of-anti-cancer-drugs-botensilimab-agen11-nct07551596 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-combination-of-venetoclax-and-rituximab-in-compariso-nct04840602 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-a-combination-targeted-therapy-vipo-nct06649812 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-the-anti-cancer-drug-mirdametinib-i-nct07061951 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-effectiveness-of-two-immunotherapy-drugs-nivolumab-a-nct03866382 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-investigational-agent-combination-of-daratumumab-bor-nct07085728 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-investigational-medication-combination-of-daratumuma-nct06948084 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-safety-and-effectiveness-of-radiation-based-treatmen-nct05691465 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-safety-and-feasibility-of-immunotherapy-drugs-botens-nct07516366 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-use-of-ado-trastuzumab-emtansine-compared-to-the-usu-nct05408845 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-the-use-of-neratinib-or-the-combination-of-neratinib-and-nct06126276 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-what-happens-when-an-immunotherapy-drug-pembrolizumab-is-nct04671667 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/testing-whether-cemiplimab-regn2810-plus-cdx-1140-given-prior-to-nct06980038 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-cosmyc-trial-combined-suppression-of-myc-nct06922318 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-miami-empire-trial-eradication-of-metastatic-pancreatic-canc-nct06843551 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-minimalist-trial-2-nct06702033 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-sappho-study-sequential-therapy-with-curative-intent-in-de-n-nct06439693 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-study-of-atezolizumab-bevacizumab-and-memantine-in-patients-nct06789757 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/the-sugar-study-sbrt-and-relugolix-for-prostate-cancer-nct06111781 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/therapy-for-newly-diagnosed-patients-with-b-cell-precursor-acute-nct06533748 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/three-schedules-of-cue-101-administered-before-surgery-or-defini-nct04852328 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/to-study-the-effect-of-inavolisib-in-combination-with-fulvestran-nct07368998 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/top-2301-neoadjuvant-chemo-for-nsclc-nct06385262 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/total-marrow-and-lymphoid-irradiation-in-combination-with-fludar-nct07582172 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/total-neoadjuvant-therapy-with-mfolfox-and-short-course-radiatio-nct04643366 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/transoral-surgical-resection-followed-by-de-escalated-adjuvant-i-nct05388773 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/treatment-for-advanced-non-small-cell-lung-cancer-with-actionabl-nct07393555 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/treatment-of-adc-refractory-breast-cancer-with-dato-dxd-or-t-dxd-nct06533826 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/triage-of-advanced-cervical-cancer-through-immunotherapy-inducti-nct05475171 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-comparing-lattice-radiotherapy-vs-moderately-dose-escalate-nct07594431 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-investigating-visugromab-and-nivolumab-with-or-without-doc-nct07246863 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-investigating-visugromab-in-combination-with-immunochemoth-nct07098988 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-2-step-atg-for-acute-gvhd-prevention-post-myeloablative-nct06315309 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-amb-05x-for-patients-with-ctdna-colorectal-cancer-after-nct06617858 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-an-alternative-cabozantinib-dosing-schedule-in-metastat-nct05263050 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-orca-t-following-reduced-intensity-or-nonmyeloablative-nct07216443 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-therapies-with-it-cdc1s-combined-w-it-trastuzamab-for-h-nct07694986 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-of-trastuzumab-deruxtecan-in-previously-treated-her2-nct06750484 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-to-study-anti-hcmv-therapy-in-breast-cancer-patients-with-nct07383649 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/trial-utilizing-metronidazole-to-optimize-the-microbiome-of-rect-nct06569368 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/turkey-tail-mushroom-for-treating-post-menopausal-women-with-her-nct06450873 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ucsd-image-guided-cognitive-sparing-radiosurgery-for-intracrania-nct04343157 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ultra-hypo-fractionated-adjuvant-whole-breast-radiation-therapy-nct06902311 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/upfront-chemotherapy-with-radiation-therapy-crt-followed-by-chem-nct07603375 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/use-of-isatuximab-dexamethasone-and-lenalidomide-in-a-go-slow-fa-nct06517017 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/using-circulating-tumor-dna-to-risk-adapt-post-operative-therapy-nct06445114 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/venetoclax-and-hma-treatment-of-older-and-unfit-adults-with-flt3-nct06317649 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/venetoclax-cladribine-low-dose-cytarabine-and-azacitidine-in-tre-nct03586609 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/venetoclax-in-combination-with-cladribine-and-cytarabine-alterna-nct06504459 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/venetoclax-plus-zanubrutinib-for-the-treatment-of-chronic-lympho-nct07734038 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/venetoclax-sl-401-and-chemotherapy-for-the-treatment-of-blastic-nct04216524 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/vismodegib-combined-with-atezolizumab-in-platinum-resistant-ovar-nct05538091 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/vismodegib-fak-inhibitor-gsk2256098-capivasertib-and-abemaciclib-nct02523014 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/vista-valproic-acid-irinotecan-and-simvastatin-for-recurrent-gli-nct07831369 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/vorasidenib-study-in-pediatric-participants-with-grade-2-astrocy-nct07286292 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/wp1066-and-radiation-therapy-in-treating-patients-with-newly-dia-nct05879250 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/xl092-for-the-treatment-of-locally-advanced-or-metastatic-radioi-nct06959641 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/xl092-in-patients-with-metastatic-castration-resistant-prostate-nct06568562 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/xl092-zanzalintinib-for-the-treatment-of-patients-with-metastati-nct06571734 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc-nct06555133 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanubrutinib-bendamustine-rituximab-prev-untreated-wm-nct06561347 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanubrutinib-obinutuzumab-sonrotoclax-boson-or-bgb-16673-obinutu-nct06849713 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanzalintinib-for-metastatic-clear-cell-renal-cell-carcinoma-wit-nct07043608 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanzalintinib-for-the-treatment-of-advanced-thyroid-cancer-befor-nct06959511 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanzalintinib-in-men-with-aggressive-variant-prostate-cancer-nct07218666 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zanzalintinib-maintenance-in-patients-with-high-grade-neuroendoc-nct06926634 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/zen003694-combined-with-talazoparib-in-patients-with-recurrent-o-nct05071937 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/phase-2/ziftomenib-for-the-treatment-of-patients-with-npm1-mutated-or-km-nct06930352 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/advanced-cancer monthly 0.7 https://www.trianglehealth.com/care-management monthly 0.7 https://www.trianglehealth.com/clinical-trials monthly 0.7 https://www.trianglehealth.com/clinics monthly 0.7 https://www.trianglehealth.com/concierge monthly 0.7 https://www.trianglehealth.com/doctors monthly 0.7 https://www.trianglehealth.com/for-developers monthly 0.7 https://www.trianglehealth.com/newly-diagnosed monthly 0.7 https://www.trianglehealth.com/oncology-practices monthly 0.7 https://www.trianglehealth.com/products monthly 0.7 https://www.trianglehealth.com/clinic monthly 0.7 https://www.trianglehealth.com/blog 2026-10-31T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/blog/how-to-get-copies-of-your-medical-records 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/prior-authorization-denial-statistics 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/median-survival-meaning 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/absolute-vs-relative-risk 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/keeping-a-medication-list 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/how-to-read-an-imaging-report 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/how-to-appeal-a-health-insurance-denial 2026-10-30T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/how-to-read-a-clinicaltrials-gov-listing 2026-09-14T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/how-to-read-a-pathology-report 2026-09-14T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/how-to-read-your-lab-results 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/phase-1-vs-phase-2-vs-phase-3-cancer-trials 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/questions-to-ask-before-joining-a-cancer-clinical-trial 2026-09-14T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/blog/what-is-a-phase-1-cancer-trial 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers 2026-11-01T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/answers/caregiver-permissions-by-portal 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/what-to-do-first-after-a-cancer-diagnosis 2026-11-01T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/getting-copies-of-mri-and-ct-scan-images 2026-10-29T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/hipaa-right-of-access 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/patient-portal-vs-full-medical-record 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/what-to-bring-to-the-er 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/medicare-blue-button 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/what-is-the-right-to-try-act 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/what-is-a-tumor-board 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/fda-approval-types 2026-10-22T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/what-is-a-treatment-guideline 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/how-to-read-a-study-abstract 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/caregiver-access-to-medical-records 2026-10-20T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/coordinating-care-with-several-doctors 2026-10-23T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/does-a-phase-1-trial-use-a-placebo 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/prior-authorization 2026-10-22T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/questions-to-ask-your-oncologist 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/biomarker-and-genomic-testing 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/clinicaltrials-gov-listings 2026-09-14T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/getting-your-medical-records 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/health-insurance-denials-and-appeals 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/joining-a-cancer-clinical-trial 2026-10-30T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/phase-1-cancer-trials 2026-09-14T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/second-opinions-and-appointments 2026-10-31T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/answers/sharing-medical-records-with-a-new-doctor 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy 2026-09-13T00:00:00.000Z weekly 0.8 https://www.trianglehealth.com/advocacy/all 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/breast 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/lung 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/prostate 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/colorectal 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/blood 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/brain 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/pancreas 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/liver 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/stomach 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/ovary 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/kidney 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/skin 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/head-neck 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/thyroid 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/sarcoma 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/childhood 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/aya 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/rare 2026-09-13T00:00:00.000Z weekly 0.7 https://www.trianglehealth.com/advocacy/groups/us-a-cure-in-sight 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-acpmp 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-act 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-action-against-heartburn 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-action-bladder-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-action-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-action-kidney-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-action-on-womb-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-aclt 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-aim-at-melanoma 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-alike 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-alk-positive 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-alliance-childhood-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-amend 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-american-cancer-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-acs-can 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-american-childhood-cancer-organization 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-american-indian-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ammf 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-andrew-mcdonough-b-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-angiosarcoma-awareness 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-anthony-nolan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-arizona-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-arkansas-prostate-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-asbestos-dust-diseases-research-institute 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-adao 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-asbestos-disease-support-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-amaa 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-australian-cervical-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-australian-pituitary-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ayrshire-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-baggy-trousers 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-balls-to-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-beat-bladder-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-beatson-cancer-charity 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-bhd-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-bladder-cancer-advocacy-network 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-bladder-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-blood-cancer-nz 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-blood-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-blood-cancer-united 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-blue-faery 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-bone-cancer-research-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-bowel-cancer-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-bowel-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-bowel-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-bowel-research-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-brain-tumour-alliance-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-brain-tumour-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-brain-tumour-research 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-brain-tumour-research-campaign 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-brain-tumour-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-brainchild-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-brainstrust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ohio-brave-men 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ie-breakthrough-cancer-research 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ny-breast-cancer-coalition-rochester 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-breast-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-breast-cancer-network-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-breast-cancer-now 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-breast-cancer-prevention-partners 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-british-thyroid-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-butterfly-thyroid-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cahonas-scotland 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-california-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-camp-quality 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-canadian-breast-cancer-network 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-canadian-cancer-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-ccsn 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-cancer-action-now 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-card 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-chicks 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-connect-ni 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-act 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-nt 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-nsw 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-queensland 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-sa 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-tasmania 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-victoria 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cancer-council-wa 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-focus-ni 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-laryngectomee-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-lifeline 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-cancer-nation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-research-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-cancer-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-cancer-support-community 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer-support-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cancer52 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-cancercare 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-canteen 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-canteen 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ie-canteen 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-care-for-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-charis-cancer-care 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-child-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-chect 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-childrens-brain-tumor-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cclg 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-childrens-cancer-cause 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-childrens-cancer-research-fund 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-childrens-tumor-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-cholangiocarcinoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cholangiocarcinoma-foundation-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-chondrosarcoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-chordoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-chordoma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-chris-cj-johnson-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-clan-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-clear-cell-sarcoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cll-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-cml-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-cml-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-coalition-priorite-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-colon-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-colorectal-cancer-alliance 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-colorectal-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-ccran 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-cooper-rice-brading-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-coppafeel 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-counterpart 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-craigs-cause 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-icureasps 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-curemec 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-cutaneous-lymphoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-david-collins-leukaemia-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-deadliest-cancers-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-debbies-dream-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-delaware-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-desmoid-tumor-research-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-dreams2live4 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-egfr-positive-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ehe-rare-cancer-charity 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-ehe-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ecan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-fanconi-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-fibrolamellar-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-fight-bladder-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-fight-colorectal-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-florida-breast-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-force 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-friends-of-anchor 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-friends-of-cancer-research 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-friends-cancer-centre 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-gallbladder-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-georgia-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-get-a-head 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-gi-cancer-institute 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-gist-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-global-liver-institute 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-go2-lung-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-grace-kelly-childhood-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-guts-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-head-and-neck-cancer-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-healthtree 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-heartburn-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-hepatitis-b-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-hope-for-stomach-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-hpv-cancers-alliance 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-imerman-angels 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-icpv 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-pink-hope 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-intercultural-cancer-council 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-international-myeloma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/intl-inca 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-iwmf 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ie-irish-cancer-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-its-in-the-bag 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-its-on-the-ball 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-jos-cervical-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-joeys-wings 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-kccure 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-kentucky-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-kidney-cancer-association 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-kidney-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-kidney-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-kidneycan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-latch 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-leiomyosarcoma-research-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-lmsdr 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/intl-lets-cure-acc 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-leukaemia-care 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-leukaemia-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-leukaemia-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-llsc 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lilac-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-livestrong 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lasag 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-lung-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-lung-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-lung-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-lungevity 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lymphoedema-support-network 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lymphoma-action 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lymphoma-out-loud 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-lynch-syndrome-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-macmillan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-maggies 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-maine-coalition-fight-prostate-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-tennessee-man2man 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ie-marie-keating-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-massachusetts-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-mattie-miracle 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-mds-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-melanoma-network-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-melanoma-focus 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-melanoma 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-melanoma-patients-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-melanoma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-mesothelioma-applied-research-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-mesothelioma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-metavivor 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-mib-agents 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-mind-over-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-move-against-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-mpn-voice 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-mummys-star 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-myeloma-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-myeloma-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-myeloma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-mpn-alliance-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-nankind 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-naspcc 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-national-brain-tumor-society 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-national-leiomyosarcoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-national-pancreas-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-nebraska-prostate-cancer-alliance 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-neuroblastoma-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-neuroblastoma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-neuroendocrine-cancer-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-neuroendocrine-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-neuroendocrine-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-netrf 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-new-hampshire-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-nord-rcc 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-nwcr 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-nirdp 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ochre 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ocular-melanoma-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ocular-melanoma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-odyssey 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ovac 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-oracle-head-neck 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-orchid 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-outpatients 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ovacome 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ovarian-cancer-action 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-ovarian-cancer-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-ovarian-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-ovarian-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ocra 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-pancare 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-pancreatic-cancer-action 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pancan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-pancreatic-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-pancreatic-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-pankind 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-patient-empowerment-network 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-peaches-womb-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pediatric-brain-tumor-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-prda 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pennsylvania-prostate-cancer-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-penny-brohn-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pheo-para-alliance 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-planets 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-pretty-n-pink 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-prevent-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-prostate-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-prostate-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-prostate-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-pcfa 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pcsanm 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-prostate-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pcec 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-prostate-scotland 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-pseudomyxoma-survivor 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-pten-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-quebec-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-rally-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-rare-cancer-research-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-rare-cancers-australia 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ray-of-light-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-rays-of-hope 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-rethink-breast-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-robin-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ros1ders-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-rowan-tree-cancer-care 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-roy-castle 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-rucker-collier-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ruth-strauss-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-salivary-gland-cancer-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-sarcoma-cancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-sarcoma-foundation-of-america 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-sarcoma-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-save-your-skin-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-sdh-ra 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-shine-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-smarcb1-hope 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-sock-it-to-sarcoma 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-solaris-cancer-care 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-solving-kids-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-sophie-fitzpatrick-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-st-baldricks 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-stupid-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-summers-way-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-susan-g-komen 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-swell-ni 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/nz-talk-peach 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-target-ovarian-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-targetcancer-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-tayside-cancer-support 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-teen-cancer-america 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-teenage-cancer-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-tenovus 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-bardo-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-boom-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-bottom-line 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-brain-tumour-charity 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-ashton-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-childrens-tumour-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-chris-lucas-trust 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ehe-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ella-dawson-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-eve-appeal 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-joshua-tree 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-tlpf 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-life-raft-group 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-paula-takacs-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-uk-mastocytosis-support-group 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-the-urology-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-think-pink-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-thyca 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-thymic-uk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-thyroid-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-thyroid-cancer-support-group-wales 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-tiger-lily-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-tom-bowdidge-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-trekstock 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-triage-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ucare 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-ukaos 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-ulman-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/intl-uicc 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ie-ucan 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-urostomy-association 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-v-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-vhl-alliance 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-vhl-uk-ireland 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-wellbeing-of-women 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-wellspring 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-wmuk 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-wcr 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/au-yellow-freesia-foundation 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-yorkshire-cancer-community 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/ca-young-adult-cancer-canada 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-young-lives-vs-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-young-survival-coalition 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/gb-young-tongues 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/advocacy/groups/us-zero-prostate-cancer 2026-09-13T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/agents 2026-10-31T00:00:00.000Z weekly 0.8 https://www.trianglehealth.com/developers weekly 0.8 https://www.trianglehealth.com/agents/claude-science 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/claude 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/chatgpt 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/grok 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/muse 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/perplexity 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/lm-studio 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/agents/other-mcp-clients 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/integrations/connect-with-triangle 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/integrations/developer-portal 2026-10-31T00:00:00.000Z monthly 0.7 https://www.trianglehealth.com/connect/ucsf 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/ucla 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/mayo 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/cleveland-clinic 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/kaiser 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/mass-general-brigham 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/johns-hopkins 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/stanford 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/nyu-langone 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/cedars-sinai 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/northwestern 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/penn-medicine 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/sutter 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/adventhealth 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/providence 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/intermountain 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/baylor-scott-white 2026-10-26T00:00:00.000Z monthly 0.6 https://www.trianglehealth.com/connect/advocate 2026-10-26T00:00:00.000Z monthly 0.6